News & Updates
Filter by Specialty:
Infliximab does not contribute to long-term weight gain in IBD patients
Treatment with infliximab does not lead to a general long-term weight gain in patients with inflammatory bowel disease (IBD), claims a study.
Infliximab does not contribute to long-term weight gain in IBD patients
20 May 2022
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
SER-109, an investigational oral microbiome therapeutic, achieves superiority over placebo in reducing recurrent Clostridioides difficile infection (CDI) rates, according to updated findings from the phase III ECOSPOR-III trial.
Investigational drug gains upper hand over placebo in reducing CDI recurrence rates
20 May 2022
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
Patients who have had a stroke despite being on nonvitamin K antagonist oral anticoagulant therapy are likely to experience a recurrent ischaemic stroke episode and bleeding, according to data from the RENO-EXTEND Study.
Stroke while on anticoagulant therapy predicts recurrence, bleeding risks
20 May 2022
Sustained benefits with ocrelizumab in relapsing-remitting MS
Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.
Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
Tofacitinib on par with TNFi in rheumatoid arthritis
Tofacitinib demonstrates similar physician- and patient-reported effectiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA), according to a study.
